- Home
- IMPP vs TARA Comparison
IMPP vs TARA Comparison
Compare IMPP & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMPP
- TARA
- Stock Information
- Founded
- IMPP 1981
- TARA N/A
- Country
- IMPP Greece
- TARA United States
- Employees
- IMPP N/A
- TARA N/A
- Industry
- IMPP Marine Transportation
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMPP Consumer Discretionary
- TARA Health Care
- Exchange
- IMPP Nasdaq
- TARA Nasdaq
- Market Cap
- IMPP 112.9M
- TARA 118.1M
- IPO Year
- IMPP N/A
- TARA N/A
- Fundamental
- Price
- IMPP $3.77
- TARA $3.07
- Analyst Decision
- IMPP
- TARA Strong Buy
- Analyst Count
- IMPP 0
- TARA 6
- Target Price
- IMPP N/A
- TARA $19.80
- AVG Volume (30 Days)
- IMPP 187.7K
- TARA 157.8K
- Earning Date
- IMPP 09-05-2025
- TARA 08-11-2025
- Dividend Yield
- IMPP N/A
- TARA N/A
- EPS Growth
- IMPP N/A
- TARA N/A
- EPS
- IMPP 1.02
- TARA N/A
- Revenue
- IMPP $127,675,263.00
- TARA N/A
- Revenue This Year
- IMPP $8.79
- TARA N/A
- Revenue Next Year
- IMPP $40.11
- TARA N/A
- P/E Ratio
- IMPP $3.69
- TARA N/A
- Revenue Growth
- IMPP N/A
- TARA N/A
- 52 Week Low
- IMPP $2.12
- TARA $1.60
- 52 Week High
- IMPP $4.55
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- IMPP 77.89
- TARA 46.15
- Support Level
- IMPP $3.20
- TARA $3.08
- Resistance Level
- IMPP $3.50
- TARA $3.30
- Average True Range (ATR)
- IMPP 0.16
- TARA 0.15
- MACD
- IMPP 0.05
- TARA 0.00
- Stochastic Oscillator
- IMPP 86.52
- TARA 28.57
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).